This guide explains the UMPJE as NABP publishes it — its structure, its scoring, its content outline, and the jurisdictions that accept it — and how the PassProfessor program maps onto each part.
Format and scoring
The UMPJE presents 120 questions over two and a half hours: 100 scored questions and 20 unscored pretest questions mixed in indistinguishably. Results are reported as pass/fail only. NABP reports no score and publishes no passing score, so no percentage of correct answers can be stated as the passing standard — which is why this program scores practice against a 70% benchmark and labels it as a benchmark. Candidates may attempt the UMPJE at most five times in total; a passing score can be transferred to other participating jurisdictions for $105 per jurisdiction within 89 days of the exam, an option the state MPJE does not offer.
Content breakdown
Every domain on NABP’s outline is covered at its published weight. The bank’s domain counts, and what a full practice exam draws from each:
- Pharmacy and Pharmacist Practice — 525 practice questions; 30 per full practice exam
- Medication Use Process — 525 practice questions; 30 per full practice exam
- Regulatory Authority and Legal Obligations — 350 practice questions; 20 per full practice exam
- Pharmacy Operations — 350 practice questions; 20 per full practice exam
Where the UMPJE counts
Thirteen jurisdictions have adopted the UMPJE in place of a state-specific MPJE. A passing score earned for one of them can be transferred to another participating jurisdiction for $105, up to 89 days after the exam.
- Arizona — UMPJE available from April 1, 2026
- Iowa — UMPJE available from April 1, 2026
- Kansas — UMPJE available from April 1, 2026
- North Carolina — UMPJE available from April 1, 2026
- Ohio — UMPJE available from April 1, 2026
- Rhode Island — UMPJE available from April 1, 2026
- Florida — UMPJE available from June 1, 2026
- Maryland — UMPJE available from June 1, 2026
- Montana — UMPJE available from June 1, 2026
- Nebraska — UMPJE available from June 1, 2026
- West Virginia — UMPJE available from June 1, 2026
- Washington — UMPJE available from July 2, 2026
- Virginia — UMPJE available from September 1, 2026
How to prepare with this program
A full practice exam draws 100 scored questions — the scored length of the real exam — across all four domains at their outline weights, inside a 150-minute limit that mirrors the real two-and-a-half-hour clock. The real exam seats 120 questions: the same 100 scored questions plus 20 unscored pretest questions mixed in; this program’s draws are scored questions only. Practice exams are scored against a 70% practice benchmark: the real UMPJE is pass/fail only — NABP reports no score and publishes no passing score — so treat the benchmark as a practice target, not an NABP standard.
Work the domain drills first to find weak areas, then take full timed practice exams as your date approaches. Because every attempt draws a fresh set from the full 1,750-question bank, your scores track what you know rather than what you have memorized.
One scoring point to be clear about: the 70% figure used inside this program is a practice benchmark only. The real UMPJE is pass/fail against a standard NABP does not publish, and no percentage — ours or anyone else’s — is the NABP passing standard.
One scope point: because the UMPJE tests federal law and the principles common across jurisdictions, this bank is built the same way. If your jurisdiction still requires its own state-specific MPJE (or its own law exam), you need preparation for that exam as well — check with your board of pharmacy which law exam it requires.
Verified questions
Every question in this program is original — written for PassProfessor from the official exam blueprint, never copied from a test bank or another provider’s materials. Before enrollment opened, each answer key was independently verified: reviewers re-answered sampled questions blind, disagreements were settled against the primary sources, and every numeric answer was recomputed from first principles. Questions whose facts could not be confirmed were removed, and the bank passed a text-overlap screen. Practice exams draw a fresh, blueprint-weighted set from the full bank on every attempt, so no two practice exams are the same.
Free study sheet (PDF): Download the MPJE federal-core study sheet — controlled-substance and DEA rules, FDA labeling, OBRA ’90, HIPAA, and USP compounding standards on two printable pages
Uniform MPJE facts, checked November 2026
| Exam | The Uniform MPJE (UMPJE), developed and administered by NABP — federal law plus the state-law principles uniform across most jurisdictions; no single state’s statutes |
| Launched | April 2026 |
| Format | 120 questions presented — 100 scored + 20 unscored pretest — computer-adaptive, 2.5 hours, at Pearson VUE; at least 107 questions must be answered to receive a result |
| Scoring | Pass/fail only, the same reporting as the MPJE — NABP publishes no numeric passing score |
| Fee | $450 per attempt — $100 application + $350 exam; NABP confirms eligibility for all UMPJE jurisdictions itself |
| Score transfer | $105 per additional participating jurisdiction, purchasable up to 89 days after the exam — the transfer the state MPJE does not offer |
| Attempts | 5 lifetime attempts |
| Adoption | 13 participating jurisdictions as of November 2026 (table below) |
| Content outline | Pharmacy and Pharmacist Practice 30% · Medication Use Process 30% · Regulatory Authority and Legal Obligations 20% · Pharmacy Operations 20% |
| This program | 1,750 original questions with an explanation for every answer, weighted to the UMPJE Content Outline; $49 with 6 months of access |
The MPJE passing score, explained
There is no numeric passing score to aim at. Since January 2021, NABP has reported MPJE and UMPJE results as pass or fail only. No scaled score, no raw score, and no percentage is published or released to candidates — so any page that tells you the passing score is a number is working from an old exam.
The number those pages quote — a scaled score of 75 — was real once. NABP’s July 2020 Candidate Application Bulletin set the minimum passing score at 75 on a 0–100 scale and said explicitly that the figure was “not a percentage value.” NABP retired scaled reporting the following January. Two errors follow the old figure around: treating it as current, and converting it into a percentage of questions (“about 70–73% correct”) — a conversion NABP’s own materials never supported, on a scale that was never a percentage of anything. Some state board rules still carry “75” wording written against the retired scale; those are dated rule texts that have not been re-drafted since the reporting change, not a score any candidate receives today.
What you can measure is your own practice. PassProfessor scores its practice simulations against a 70% practice benchmark and labels it as a benchmark — a preparation target, never an NABP standard. A candidate who is consistently clearing that benchmark across full-length, blueprint-weighted practice exams — federal and state law intermixed, the way the real exam presents them — is preparing against the standard that exists, rather than a number that no longer does.
MPJE vs UMPJE: what is the difference?
The MPJE is one exam per jurisdiction: it tests federal law and that jurisdiction’s own statutes, intermixed with no distinction between them, and a pass applies only to the jurisdiction tested — MPJE scores cannot transfer. The Uniform MPJE (UMPJE), launched by NABP in April 2026, tests federal law plus the state-law principles that are uniform across most jurisdictions, so one pass can serve several states: a UMPJE score transfers to an additional participating jurisdiction for $105, purchasable up to 89 days after the exam. The delivery is the same for both — 120 questions presented (100 scored + 20 unscored pretest), computer-adaptive, 2.5 hours, pass/fail only — but the price and attempt rules differ: the MPJE costs $270 per attempt per jurisdiction ($355 in the 12 jurisdictions where NABP confirms eligibility) with up to 5 attempts per jurisdiction, while the UMPJE costs $450 per attempt with 5 lifetime attempts.
Thirteen jurisdictions had adopted the UMPJE as of November 2026, per NABP’s participating-states table. A candidate who passed a jurisdiction’s MPJE before its retirement date generally does not retake the UMPJE for that jurisdiction — confirm with the board — and appointments scheduled on or after a retirement date are canceled by NABP with a full refund.
| Jurisdiction | UMPJE from | State MPJE through |
|---|---|---|
| Arizona | April 1, 2026 | March 31, 2026 |
| Iowa | April 1, 2026 | March 31, 2026 |
| North Carolina | April 1, 2026 | March 31, 2026 |
| Rhode Island | April 1, 2026 | March 31, 2026 |
| Ohio | April 1, 2026 | September 30, 2026 |
| Kansas | April 1, 2026 | March 31, 2027 |
| Florida | June 1, 2026 | May 31, 2026 |
| Montana | June 1, 2026 | May 31, 2026 |
| West Virginia | June 1, 2026 | August 1, 2026 |
| Maryland | June 1, 2026 | May 31, 2027 |
| Nebraska | June 1, 2026 | May 31, 2028 |
| Washington | July 2, 2026 | December 29, 2026 |
| Virginia | September 1, 2026 | September 30, 2026 |
None of the 13 adopting jurisdictions is a state whose MPJE program PassProfessor sells today — every PassProfessor MPJE program still maps to a live state-specific exam. One more state is in motion: the Oregon Board of Pharmacy has proposed moving Oregon to the UMPJE effective April 1, 2027 (rulemaking filed October 9, 2026).
What about the official Pre-UMPJE?
NABP sells its own official practice exam, the Pre-UMPJE (and the Pre-MPJE for the other exam): $90 per attempt, 40 questions, 50 minutes, online and unproctored, drawn from retired real exam items. It is the only official set of retired questions, and as a one-time trial run it does something no practice bank can — it shows you NABP’s own item style at full fidelity. What it cannot do is carry a preparation: 40 questions, taken once or twice a year, against a 1,500-plus-question bank with fresh draws, per-area drills, and an explanation for every answer. The two products complement each other — the official practice exam as the trial run, the bank as the training.
Worked practice questions
Thirty-two questions from the Uniform MPJE bank, worked in full — the question, the four options, the keyed answer, and the explanation the program gives for it — distributed across the four UMPJE content domains at their outline weights. None of the 32 is in the free sample.
Pharmacy and Pharmacist Practice
1. A patient with a new, undiagnosed symptom asks the pharmacist to simply issue a prescription for a prescription-only drug, without any prescriber order, protocol, or collaborative agreement covering it. The patient notes the pharmacist 'knows medicines better than anyone.' What is the appropriate response?
A. Issue the prescription, because medication expertise alone confers prescribing authority
B. Explain that issuing a prescription without a prescriber order or delegated authority is outside the pharmacist's scope, and refer the patient for prescriber evaluation while offering any counseling or over-the-counter help that is within scope
C. Have an intern write the prescription under the pharmacist's supervision instead
D. Dispense the drug as a professional sample so no prescription is needed
Correct: B. Dispensing rests on a valid prescriber order or a specific delegated or protocol authority; general medication expertise does not create independent authority to issue a prescription, so referral for evaluation is required. A is wrong because expertise and authority are different things. C is wrong because an intern cannot create authority the supervising pharmacist does not have, and D is wrong because relabeling a dispensing as a sample does not remove the prescription requirement.
2. A collaborative agreement names the clinic's pharmacists as the clinicians authorized to order and interpret certain lab tests and to act on the results. On a busy day, a pharmacist asks a well-trained technician to interpret a potassium result and decide whether a dose change is needed under the agreement. How should this be handled?
A. The pharmacist must do the interpretation and make the decision personally; the technician may gather and file the result for the pharmacist's review
B. The technician may interpret the result and change the dose if the pharmacist reviews the decision later in the week
C. The technician may decide because national certification qualifies a technician to interpret labs under an agreement
D. The interpretation may be delegated whenever the patient appears stable
Correct: A. Delegated authority under a collaborative agreement runs to the pharmacist, and interpreting a lab result to decide a therapy change is clinical judgment, so the pharmacist must do it personally while the technician's role stays mechanical, making A correct. B is wrong because review after a dose has already been changed does not cure an unauthorized decision. C is wrong because technician certification does not confer clinical interpretation authority, and D is wrong because apparent stability does not expand a technician's scope.
3. In a hospital cleanroom suite, a technician hired last week is scheduled to prepare a batch of sterile intravenous preparations. She has not yet completed the garbing, hand hygiene, fingertip sampling, and media-fill competency assessments required for sterile compounding personnel. What should the pharmacist in charge do?
A. Hold the sterile compounding assignment until her competency training is completed and documented, and assign her supervised non-compounding work in the meantime
B. Let her prepare the batch if the pharmacist watches her compound the first container
C. Let her prepare the batch wearing gloves and a gown, since protective clothing substitutes for competency assessment
D. Let her prepare the batch because her previous retail pharmacy experience counts as sterile compounding competency
Correct: A. A is correct because sterile compounding requires documented personnel competency, including garbing, hand hygiene, fingertip sampling, and media-fill assessment, before a technician performs that work. B is wrong because watching a first container does not replace the required competency assessments. C is wrong because wearing protective clothing is part of proper garbing practice, not a substitute for being assessed and documented as competent. D is wrong because general retail experience is not sterile compounding competency.
4. An unfamiliar seller offers the pharmacy brand-name injectables at prices well below every established wholesaler. Before any purchase, what is the pharmacist's supply-chain obligation?
A. Verify that the seller is an authorized trading partner before buying
B. Buy a small amount first, since small purchases carry no verification duty
C. Buy only if the seller has a professional-looking website and invoices
D. Buy freely, because price competition among sellers is unrestricted
Correct: A. Track-and-trace rules require pharmacies to deal with authorized trading partners, so the seller's status must be verified before purchasing (A). Purchase size (B) does not remove the verification duty. A polished website and invoices (C) are not proof of authorized status, and unusually low prices from an unknown source (D) are a classic warning sign, not unrestricted competition to exploit.
5. At intake, a patient tells the pharmacy technician she developed a rash after taking penicillin last year and asks whether that means she must also avoid a newly prescribed related antibiotic. What should the technician do?
A. Decide herself that the related antibiotic is safe, because a rash is too minor to matter
B. Delete the penicillin entry from the profile, because the patient is unsure of the exact dates
C. Enter the reported penicillin reaction into the patient profile as stated and alert the pharmacist to assess its significance before the new drug is dispensed
D. Tell the patient allergy information is only collected at the first fill and cannot be added now
Correct: C. C is correct because recording what the patient reported is mechanical data entry, while judging whether a prior reaction affects a related drug is clinical assessment for the pharmacist, supported by a profile that includes allergies. A is wrong because the technician may not make that safety decision herself. B is wrong because deleting allergy information destroys data prospective review depends on, and D is wrong because profiles are maintained and updated, not frozen after intake.
6. A pharmacy migrating to new compounding software is told by the vendor that it can purge its existing compounding logs, personnel competency and training files, and environmental monitoring and quality assurance records so the new system starts clean. What should the pharmacy do?
A. Purge the records, because they served their purpose when they were created
B. Retain the records, because compounding, competency, environmental testing, and quality assurance documentation must be kept and remain retrievable; a software change is not a basis for destroying them
C. Purge the competency files but keep only the master formulation records
D. Purge everything older than 30 days, keeping only the current month
Correct: B. B is correct: compounding records, competency and training documentation, environmental testing results, and quality assurance records must be retained and retrievable — they are the pharmacy's proof of what was made, by whom, and under what conditions — and changing software does not end that duty. A is wrong: the records' purpose includes later review, investigation, and inspection, which continue after the day they were created. C is wrong: competency documentation is part of the required record set, not an optional extra. D is wrong: a 30-day purge would destroy records the pharmacy is required to keep well beyond that window.
7. A patient reports a serious, unexpected reaction shortly after starting a drug the pharmacy dispensed, and a separate patient reports a serious event after a vaccine the pharmacy administered. What reporting action belongs in the pharmacist's practice?
A. Wait to see whether more patients report the same problem before reporting anything
B. Report drug adverse events through FDA MedWatch and vaccine adverse events through the vaccine adverse event reporting system, as applicable to each event
C. Report both events only to the store manager and keep them out of external systems
D. Tell both patients that reporting is solely the prescriber's responsibility
Correct: B. Pharmacists participate in adverse event reporting, using MedWatch for drug events and the vaccine reporting system for vaccine events. A is wrong because a serious report should not be held pending a pattern. C is wrong because internal notice alone does not satisfy external safety reporting, and D is wrong because the pharmacist who dispensed or administered the product shares the reporting role rather than shifting it entirely to the prescriber.
8. A lot of oral tablets is recalled only because the carton was printed with an expiration month one month earlier than the true date. The tablets themselves meet every standard, patients who use them by the printed date receive a fully potent product, and the reviewing agency concludes the error is not likely to cause adverse health consequences. How is this recall classified?
A. Class III, because the defect is unlikely to cause harm
B. Class I, because an incorrect date on a carton destroys traceability
C. Class II, because any printing error on a carton must cause at least temporary harm
D. Misbranding only, with no recall class available for a dating error
Correct: A. A is correct because a defect unlikely to cause adverse health consequences is a Class III recall. B is wrong because Class I requires a reasonable probability of serious harm or death, which a conservatively early printed date does not create. C is wrong because Class II requires likely temporary harm, and the review concluded harm is not likely here. D is wrong because a recall classification can rest on a labeling or dating defect; the defect's category does not remove it from the recall classes.
9. A sterile preparation compounded in an ISO 5 primary engineering control in a segregated compounding area sits at room temperature on a ward for 14 hours. A nurse then refrigerates it and proposes using it within 24 hours of refrigeration, arguing that the refrigerated limit now applies. What do the limits for this category require?
A. The nurse is correct; moving the preparation to the refrigerator restarts its dating with a fresh 24-hour limit
B. It may be used if a pharmacist inspects it and documents that it still looks clear
C. It may be used because the room-temperature and refrigerated limits may be added together, giving 36 hours in total
D. It may not be used: the preparation already exceeded this category's room-temperature limit of 12 hours, and later refrigeration does not restore it
Correct: D. D is correct: Category 1 limits are no more than 12 hours at room temperature or 24 hours refrigerated, and once the preparation spent 14 hours at room temperature it exceeded the limit that governed its storage; refrigeration afterward does not reset or extend it. A is wrong because the refrigerated limit is not a fresh clock that starts whenever a product is moved. B is wrong because visual clarity does not override a beyond-use limit. C is wrong because the two storage limits are alternatives, not periods that can be added together.
10. Under a written collaborative practice agreement, a pharmacist makes a medication change the agreement expressly permits for an enrolled patient. The agreement requires the pharmacist to record the care provided and to communicate the change to the collaborating prescriber. Which course of action satisfies the pharmacist's obligations?
A. Document the change in the patient's care record and communicate it to the collaborating prescriber as the agreement requires
B. Keep a private note for personal reference, since the change was already authorized in advance
C. Document the change but communicate it only if the patient later reports a problem
D. Rely on the prescriber discovering the change at the patient's next routine clinic visit, with no record made by the pharmacist
Correct: A. A is correct: acting under a collaborative practice agreement requires the pharmacist to document the care provided and communicate with the collaborating prescriber as the agreement specifies. B is wrong because a private personal note is not the care record the agreement requires and gives the prescriber no notice. C is wrong because communication is a standing term of the delegation, not something triggered only by a problem. D is wrong because leaving the change unrecorded and undiscovered defeats both the documentation and communication duties.
Medication Use Process
11. On the same afternoon, a patient presents two new prescriptions written by two different prescribers at different clinics. Neither has been dispensed. Reviewing them together against the profile, the pharmacist identifies a clinically significant interaction between the two new drugs. What should happen?
A. Dispense the prescription that was presented first and hold the second one indefinitely without contacting anyone.
B. Dispense both, because each prescriber is responsible only for the prescription that prescriber wrote.
C. Dispense both and let the patient choose which one to start.
D. Resolve the interaction concern before dispensing, contacting the prescribers as needed to obtain a change or a monitoring plan.
Correct: D. D is correct: prospective review screens for drug interactions before dispensing, and the fact that the interacting drugs come from two prescribers does not remove the concern; it must be resolved, with prescriber contact when a change or monitoring plan is needed. A is wrong because silently holding one prescription resolves nothing and leaves a prescriber uninformed. B is wrong because interaction screening is the pharmacist's own prospective-review duty, not divided away between prescribers. C is wrong because choosing between interacting therapies is a clinical decision for the prescribers and pharmacist, not an uninformed patient choice.
12. A long-term care facility patient has received a Schedule II medicine through a series of partial fills. On day 65 after the original prescription was issued, the facility asks the pharmacy to dispense the still-undispensed remainder of that same prescription. What is the correct outcome?
A. Dispense the remainder, because partial fills for facility patients may continue indefinitely
B. Dispense the remainder if the prescriber telephones approval that day
C. Do not dispense the remainder under that prescription, because partial fills for terminally ill and long-term care patients are permitted over 60 days, after which a new prescription is needed
D. Dispense half the remainder now and the rest the following week
Correct: C. C is correct: the extended partial-fill window for terminally ill and long-term care patients runs 60 days; beyond it the undispensed balance cannot be supplied under the original prescription and a new prescription is required. A is wrong because the 60-day allowance is a defined limit, not an open-ended one. B is wrong because a telephone approval does not revive the expired partial-fill authority or substitute for a new Schedule II prescription. D is wrong because splitting the balance does not change the fact that the window has closed.
13. A pharmacist's own records show a patient has filled the same Schedule II pain medicine early three times in two months, each time at a different location in the chain, with overlapping supplies still on hand. The newest prescription is complete in every element and properly signed. What is the pharmacist's best course?
A. Fill it without inquiry, because a facially complete and signed prescription must always be dispensed
B. Resolve the overlapping, early-fill pattern before dispensing, because the pharmacist shares responsibility for whether the prescription serves a legitimate medical purpose in the usual course of practice
C. Fill only the portion not overlapping the earlier supplies and discard the rest of the order
D. Ask the patient to have the next prescription written for a larger quantity to reduce fill frequency
Correct: B. B is correct because corresponding responsibility means a pharmacist must address red flags such as repeated early, overlapping fills before dispensing, even when the document itself is complete. A is wrong because facial completeness does not end the pharmacist's responsibility for legitimacy. C is wrong because trimming the quantity does not resolve whether the underlying prescription and pattern are legitimate, and D is wrong because increasing the quantity would worsen, not resolve, the accumulation concern.
14. A Schedule IV prescription with refills remaining was already transferred once between two pharmacies that share no record system. The patient now wants it at a third pharmacy, and the prescriber offers to telephone the third pharmacy to 'approve a second transfer.' What is the workable path?
A. The prescriber's phone approval creates a valid second transfer
B. The third pharmacy may accept a second transfer if the first transfer is documented in full
C. The patient must wait until the current prescription expires and start over with no medicine in the meantime
D. The one-transfer limit is not cured by prescriber approval of another transfer; the prescriber can instead issue a new prescription directly to the third pharmacy
Correct: D. D is correct: for pharmacies without a shared record system, refill information may be transferred once; a prescriber's verbal blessing does not create a second transfer, but the prescriber remains free to issue a new prescription to the pharmacy the patient now prefers. A is wrong because the limit governs the transfer mechanism itself, not the prescriber's wishes about it. B is wrong because complete documentation of the first transfer does not authorize a second one. C is wrong because a new prescription from the prescriber is an available path, so the patient is not forced to go without therapy until expiry.
15. A technician, trying to make every prescription 'comply' with child-resistant packaging rules, transfers a patient's sublingual nitroglycerin tablets out of the manufacturer's container into a child-resistant vial before dispensing. The pharmacist stops the technician. Why?
A. Because nitroglycerin must instead be transferred into an easy-open container chosen by the technician
B. Because only the patient may ever handle the manufacturer's container for this drug
C. Because the tablets should have been counted twice before any transfer, and the count was skipped
D. Because sublingual nitroglycerin is an exception to the child-resistant packaging requirement, so forcing it into a child-resistant vial to 'comply' misapplies the rule
Correct: D. D is correct because nitroglycerin is one of the recognized exceptions to child-resistant packaging, so the requirement the technician was enforcing does not apply to this product. A is wrong because the exception does not direct a technician-selected easy-open transfer either; the point is that the child-resistant mandate does not govern this drug. B is wrong because the exception is about the packaging requirement, not about who may touch the container. C is wrong because the problem is the misapplied packaging rule, not a counting step.
16. A long-term care resident's Schedule II prescription was first partially filled 75 days ago, and the facility now requests one more small increment from that same prescription to finish the week. What should the pharmacist do?
A. Dispense it, because partial fills for facility residents may continue for up to six months
B. Decline to dispense from that prescription, because the 60-day period for Schedule II partial fills for long-term care patients has passed and a new prescription is needed
C. Dispense it if the facility nurse authorizes the increment verbally
D. Dispense it, because each increment restarts a fresh 60-day period
Correct: B. Schedule II partial fills for long-term care patients are permitted over a period of up to 60 days; at 75 days that period has run, so a new prescription is required (B). The allowance is not six months (A). A nurse's verbal authorization (C) cannot extend a prescription's partial-fill period, and increments do not restart the clock (D) — the period runs from the prescription, not from the last increment.
17. On the same day, a pharmacy learns of two serious events. One patient was hospitalized after a vaccine the pharmacist administered at the pharmacy. Another patient was hospitalized with a serious reaction clinicians attribute to a non-vaccine prescription drug the pharmacy dispensed. Which pairing of federal reports is correct?
A. Both events go through the drug adverse event system, because the pharmacy dispensed or administered both products
B. The vaccine event is reported through the vaccine adverse event reporting system, and the non-vaccine drug event is reported through FDA MedWatch
C. Both events go through the vaccine adverse event reporting system, because both patients were pharmacy patients on the same day
D. Neither event is reported federally, because the pharmacy did not manufacture either product
Correct: B. B is correct because adverse events following vaccines are reported through the vaccine adverse event reporting system, while serious reactions to drugs that are not vaccines are reported through FDA MedWatch, and the two events here fall one into each system. A is wrong because it routes the vaccine event into the drug system. C is wrong because it routes the prescription drug event into the vaccine system merely because the events arose on the same day. D is wrong because federal adverse event reporting is not limited to manufacturers; pharmacists report events involving products they administer and dispense.
18. A trained, certified pharmacist administers vaccines under a written protocol that covers specified vaccines for adult patients. A 16-year-old, accompanied by a parent who consents, asks the pharmacist for a vaccine the protocol lists, but the protocol's defined patient population is adults. What should the pharmacist do?
A. Decline to administer it under that protocol and refer the family to an appropriate provider, because the pharmacist must act within the protocol's defined patients and this patient falls outside them
B. Administer it, because a parent's consent expands the protocol to cover the child
C. Administer it, because the vaccine itself is listed in the protocol and that is the only limit that matters
D. Have the parent sign a waiver and then administer it under the protocol
Correct: A. A is correct because authority exercised under a protocol or collaborative arrangement is bounded by its defined conditions, including the patients it covers, and a patient outside the defined population must be referred rather than treated under that authority. B is wrong because parental consent, while relevant to care generally, does not amend the protocol's patient population. C is wrong because the protocol's limits include both the vaccines and the patients specified, not the vaccine list alone. D is wrong because a waiver cannot extend delegated authority beyond the protocol's boundaries.
19. In a jurisdiction that mandates a prescription drug monitoring program check before dispensing opioids, a manager proposes skipping the check whenever a patient pays cash, reasoning that no insurer is involved to require documentation of the check. What is the correct position?
A. Skip the check for cash-paying patients the pharmacy knows well
B. Run the check for cash patients only if an insurer later audits the fill
C. Perform the mandated check before dispensing regardless of how the prescription is paid for, and document the check
D. Let the patient choose whether the check is run, since paying cash makes the fill a private transaction
Correct: C. C is correct: where a monitoring-program check is mandated before dispensing, the mandate attaches to the dispensing of the controlled substance, not to the payment method, so the check is performed and documented for cash fills as for any other. A is wrong because familiarity with the patient and cash payment are not exceptions to a mandated check. B is wrong because a check run after an audit request is not a check performed before dispensing. D is wrong because a mandated check is not the patient's to decline in exchange for paying cash.
20. A pharmacy repackages tablets from a manufacturer's bottle into large amber stock bottles for use at its own satellite locations; this is not unit-dose packaging. The manufacturer's expiration date is ten months away, but a technician dates the stock bottles sixteen months out, reasoning that stock bottles need dating room. What is the correct dating limit?
A. No later than the manufacturer's expiration date ten months away, because a repackaged product's assigned date may never exceed the manufacturer's expiration date
B. Sixteen months, because non-unit-dose stock bottles may carry dating beyond the manufacturer's date
C. Six months, because every form of repackaging, including stock bottles, is capped at six months
D. Twenty-four months from repackaging, because the manufacturer's date applies only to unopened original containers
Correct: A. A is correct because the governing limit for this repackaging is that the assigned date may never exceed the manufacturer's expiration date, which is ten months away. B is wrong because no form of repackaging earns dating beyond the manufacturer's expiration date. C is wrong because the six-month figure in the fact base is framed for unit-dose repackaging, and this scenario turns on the never-exceed-the-manufacturer rule for stock bottles. D is wrong because opening and repackaging a container does not free the product from the manufacturer's expiration date.
Regulatory Authority and Legal Obligations
21. A pharmacist who has developed a substance-use problem seeks help before patients are harmed and asks whether any structured path exists other than hiding the problem. What best reflects the prevailing approach?
A. Hide the problem and keep practicing while impaired, because seeking help guarantees permanent loss of licensure
B. Turn the matter over to the Food and Drug Administration, which runs pharmacist recovery monitoring nationally
C. Use a board recovery or monitoring program where available, with practice conditioned on compliance with monitoring
D. Accept that no board offers any monitoring option and that lifetime exclusion is the only possibility in every case
Correct: C. Many boards operate recovery and monitoring programs for impaired practitioners, allowing conditional, monitored practice rather than concealment. Practicing while impaired endangers patients, the food and drug agency does not run such state monitoring, and a universal lifetime ban misstates the availability of recovery programs.
22. A prescriber orders a brand-name drug and does not prohibit substitution. The pharmacy stocks a generic from another maker that is cheaper, but the federal therapeutic-equivalence listings do not rate that generic as interchangeable with the brand. A technician urges dispensing it anyway because both products contain the same active ingredient. What may the pharmacist do?
A. Dispense the cheaper generic, because sharing an active ingredient alone establishes interchangeability
B. Dispense the cheaper generic after noting the substitution on the label
C. Seek permission from the federal controlled-substance agency, which decides all substitution questions
D. Not treat the unrated generic as an interchangeable equivalent; a pharmacist may dispense an FDA-approved generic equivalent rated interchangeable when the prescriber has not prohibited substitution
Correct: D. D is correct: drug product selection rests on the federal therapeutic-equivalence ratings, under which a generic rated interchangeable may be dispensed unless the prescriber prohibits substitution, and a product without that rating may not simply be assumed equivalent. A is wrong because containing the same active ingredient does not by itself establish therapeutic equivalence. B is wrong because documenting an improper substitution on the label does not make the unrated product interchangeable. C is wrong because substitution decisions are governed by the equivalence ratings and the prescriber's direction, not by case-by-case approval from the controlled-substance agency.
23. At a clinic pharmacy, a patient picking up a new medicine asks a clinical question about how to take it. The pharmacist is verifying orders, a pharmacy intern working under the pharmacist's direct supervision is at the counter, and an experienced technician is also present. Who may respond to the patient?
A. The technician may counsel, because long experience substitutes for pharmacist supervision
B. The technician may counsel as long as the pharmacist is somewhere in the building
C. The intern may counsel only if the technician first screens the question and approves the answer
D. The intern, working under the pharmacist's supervision, may counsel the patient; the technician may offer the pharmacist's counseling but may not answer clinical questions
Correct: D. D is correct: counseling is performed by the pharmacist, or by an intern under the pharmacist's supervision, while technicians may offer the pharmacist's counseling but cannot themselves counsel or answer clinical questions. A is wrong because experience does not expand a technician's scope into counseling. B is wrong because the pharmacist's mere presence in the building does not authorize a technician to counsel. C is wrong because a technician has no authority to screen and approve clinical answers; supervision of the intern runs through the pharmacist.
24. A board learns that a pharmacist is repeatedly reporting to work impaired and diverting medication, creating an immediate risk to patients who are being served that day. Which board action fits this situation?
A. The board must wait a full year before taking any action so the pharmacist can finish current shifts
B. The board may only send a private warning, because suspension always requires a completed civil trial first
C. The board must ask the federal drug enforcement agency to decide before it can protect patients
D. The board may summarily suspend the license where there is imminent danger, pending further proceedings
Correct: D. Where imminent danger is present, a board may use summary suspension to stop practice quickly while the case proceeds. Delaying for a year or only warning would leave the danger in place, and state board discipline does not depend on first obtaining a federal registration decision or a civil verdict.
25. A pharmacy takes a fresh biennial inventory 18 months after its previous one, to align with a remodel. The pharmacist-in-charge then discards the previous inventory sheets, reasoning that the new inventory has replaced them and the sheets are no longer the current figures. The discarded sheets were 18 months old. What is the correct assessment?
A. The discard was proper, because a newer inventory supersedes the older one for all purposes
B. The discard was proper, because inventory sheets are working papers rather than records
C. The discard was improper, because inventory records are controlled-substance records that must be kept for at least 2 years, whether or not a newer inventory exists
D. The discard was improper only if the new inventory showed a discrepancy
Correct: C. C is correct: a biennial inventory is itself a controlled-substance record subject to the federal floor of at least 2 years' retention, so sheets discarded at 18 months were destroyed early even though a newer inventory had been taken. A is wrong because a newer inventory updates the count going forward but does not erase the retention duty for the earlier record. B is wrong because inventory lists are part of the controlled-substance records the pharmacy must keep. D is wrong because the retention duty applies to the record itself, not only when a discrepancy appears.
26. A pharmacy that serves as an authorized collection point for the public's unwanted medications proposes dropping its own expired Schedule II stock into its collection receptacle, to avoid reverse-distributor fees. Why is that the wrong channel for the pharmacy's stock?
A. It is acceptable, because anything placed in the receptacle is destroyed the same way
B. It is acceptable, as long as the stock is logged as though a patient had returned it
C. It is acceptable for small quantities of expired stock, though not for large ones
D. Collection through a take-back receptacle is the channel for the public's unwanted medications; a registrant's own stock must go through the registrant disposal process, documented on the federal disposal form and handled directly or through a reverse distributor
Correct: D. Take-back collection exists for unwanted medications surrendered by the public, while a registrant disposing of its own stock uses the registrant disposal process — documented on DEA Form 41 and carried out directly or through an authorized reverse distributor (D). A is wrong because shared destruction at the end does not make the public collection channel a registrant disposal route. B is wrong because logging the pharmacy's stock as a patient return misdescribes whose medication it is, and C is wrong because the channel distinction does not depend on how much stock is involved.
Pharmacy Operations
27. At closing, a pharmacy leaves several filled controlled-substance prescriptions in an unlocked drive-through drawer overnight so the morning crew can hand them out quickly when the window opens. A technician asks whether the arrangement is a problem. What is the answer?
A. It is fine, because the drawer is on the pharmacy side of the window
B. It is fine if the prescriptions are in stapled bags with patient labels
C. It is fine on nights when the store's main alarm is set
D. It is a problem; filled prescriptions, especially controlled substances, must remain in the pharmacy's secured storage under its control until they are handed to the patient or the patient's identified recipient
Correct: D. D is correct: filled prescriptions must stay in secured storage under the pharmacy's control until handoff, and controlled substances require locked or otherwise properly secured storage; an unlocked drawer overnight satisfies neither duty. A is wrong because the drawer's location does not make unlocked overnight storage secure. B is wrong because bagging and labeling address identification, not security of the stock. C is wrong because the building alarm does not replace secured storage for the medications themselves.
28. A pharmacy faxes a refill-authorization request to a prescriber's office for a patient's non-controlled maintenance medicine. The prescriber signs the returned fax in the office, authorizing the refill, and faxes it back from the office fax line with all order elements complete. A trainee asks whether the pharmacy may rely on the returned fax. What is correct?
A. The pharmacy may treat the signed fax returned from the prescriber's office as the authorization and dispensing record for this non-controlled prescription
B. The pharmacy may not rely on it, because a fax connected with a prescription is never usable as a record
C. The pharmacy may rely on it only if the patient also brings in the prescriber's paper original
D. The pharmacy may rely on it only if a technician, rather than the prescriber, signed the returned page
Correct: A. A is correct: a fax that originates from the prescriber's office and bears the prescriber's signature may serve as the dispensing record for most prescriptions, and this returned authorization for a non-controlled medicine meets that description. B is wrong because it denies the general rule that a compliant fax serves as the record outside the Schedule II limits. C is wrong because no follow-up paper original is required for a compliant fax of a non-controlled prescription. D is wrong because the signature that matters is the prescriber's; a technician's signature could not authorize a refill.
29. A pharmacist returning to practice after several years in industry points to a current national specialty certification in her clinical area and asks to begin verifying prescriptions while her lapsed state license renewal is still pending. What should the pharmacist-in-charge say?
A. She may verify, because current specialty certification proves present competence to practice
B. She may verify non-controlled prescriptions only until the renewal posts
C. Specialty certification is an added credential, not a substitute for an active state pharmacist license, so she may not practice as a pharmacist until the board renews the license
D. She may practice under the pharmacist-in-charge's license while her renewal is pending
Correct: C. C is correct because the authority to practice comes from an active license issued by the board; a specialty certification supplements a license but does not replace it. A is wrong because demonstrated competence and legal authority are different things. B is wrong because an inactive license does not support a narrowed form of practice, and D is wrong because one pharmacist's license does not cover another person's practice.
30. A prescriber wants to send an electronic order for a Schedule II pain medicine from the clinic system. What must be in place before that electronic order can be treated as valid?
A. The clinic may use any shared office password as long as the prescriber later initials a printout
B. The prescriber must authenticate with two factors and the system must meet federal requirements for electronic controlled-substance prescribing
C. The pharmacist may accept a screenshot of the signed order sent from a personal phone instead of a compliant transmission
D. A medical assistant may apply the prescriber's electronic signature when the prescriber is busy
Correct: B. The keyed choice is right because electronic prescribing of a controlled substance requires the prescriber's two-factor authentication through compliant software. A shared password in option A is not two-factor authentication by the prescriber, a screenshot in option C bypasses the compliant system, and option D improperly lets another person apply the prescriber's signature.
31. A technician drops a glass bottle of a Schedule III medication on the pharmacy floor and the tablets are shattered and contaminated. The store manager reaches for the federal theft-and-loss form to report the incident. What is the correct handling?
A. Breakage and spillage are documented in the pharmacy's own records, with witness attestation, rather than reported on the theft-and-loss form, and the destroyed stock is handled through the registrant disposal process
B. Complete the theft-and-loss form, because every loss of a controlled substance is reported the same way
C. Sweep up and discard the tablets with no documentation, because nothing was stolen
D. Count the incident as a theft by an unknown person so the paperwork matches the inventory shortage
Correct: A. Breakage and spillage are not reported on the theft-and-loss form; they are documented in the pharmacy's records with witness attestation, and destroyed stock goes through the registrant disposal process. B wrongly treats a breakage event as a theft or significant loss for reporting purposes. C is wrong because the absence of theft does not remove the documentation duty, and D falsifies the event by recording an accident as a theft.
32. Through a pharmacy's online refill portal, a patient sends a message with her refill request for a maintenance tablet: 'Please refill this, and double the dose — I have been running out early.' There is no prescriber authorization for any change; the prescription on file is for the original dose. A technician proposes entering the refill at the doubled dose, since the request arrived through the pharmacy's own electronic system. What should happen?
A. Enter the doubled dose, because a request sent through the pharmacy's electronic portal functions as an electronic prescription
B. Do not dispense the changed dose on the patient's request; the portal message is a refill request, not a prescription, and a dose change requires authorization from the prescriber
C. Dispense three days of the doubled dose as an emergency supply while the prescriber is contacted
D. Ask the patient to send the same portal message a second time so the change is confirmed electronically
Correct: B. B is correct: a prescription, including any change to the dose of an existing one, must come from an authorized prescriber with the required prescription elements; a patient's own portal message requests a refill but authorizes nothing, and the pharmacy must obtain the prescriber's authorization before dispensing a different dose. A is wrong because the channel does not determine the document's character — an electronic prescription originates from the prescriber's system, not from a patient's account on a refill portal. C is wrong because emergency-supply principles preserve a patient's existing maintenance therapy when interruption threatens; they do not authorize dispensing a new, higher dose the prescriber never ordered. D is wrong because repeating an unauthorized request does not make it authorized.
PassProfessor scores its practice simulations against a 70% practice benchmark and labels it as a benchmark — a preparation target, never an NABP standard. Continue with the 20 free sample questions or enroll in the Uniform MPJE program — $49 for the full bank.
Frequently asked questions
What is the Uniform MPJE?
The UMPJE is NABP’s uniform pharmacy law exam, launched in April 2026. It tests federal law plus the state-law principles uniform across most jurisdictions — no single state’s statutes — and a passing score can transfer to other participating jurisdictions.
How many questions are on the UMPJE, and how long do you get?
120 questions are presented — 100 scored and 20 unscored pretest — in 2.5 hours, computer-adaptive at Pearson VUE. You must answer at least 107 of the 120 to receive a result.
What score do you need to pass the UMPJE?
There is no published numeric score. Like the MPJE, the UMPJE has been reported pass/fail only since it launched; the “scaled score of 75” sometimes quoted is the pre-2021 MPJE standard and has never applied to the UMPJE. PassProfessor scores practice against a labeled 70% practice benchmark — a preparation target, never an NABP standard.
How much does the UMPJE cost?
$450 per attempt — a $100 application fee plus the $350 exam fee. Transferring your score to an additional participating jurisdiction costs $105, purchasable up to 89 days after the exam.
Which states use the UMPJE?
Thirteen jurisdictions as of November 2026: Arizona, Florida, Iowa, Kansas, Maryland, Montana, Nebraska, North Carolina, Ohio, Rhode Island, Virginia, Washington, and West Virginia — each with its own adoption and MPJE retirement dates, tabled in this guide.
Can a UMPJE score transfer to another state?
Yes — that is the UMPJE’s defining advantage. A score transfers to an additional participating jurisdiction for $105 within 89 days of the exam. MPJE scores, by contrast, never transfer.
How many times can you take the UMPJE?
Up to 5 attempts in total — a lifetime limit, unlike the MPJE’s 5 attempts per jurisdiction.
What does this program include?
1,750 original practice questions weighted to the UMPJE Content Outline, with an explanation for every answer, full-length practice exams, and per-domain drills — $49 with 6 months of access. Start with the 20 free sample questions.
